Celltrion Completes Global Patent Agreement for Avastin Biosimilar 'CT-P16'

[Asia Economy Reporter Lee Gwan-joo] Celltrion announced on the 20th that it has completed a global patent agreement with Genentech, the developer of the blockbuster anticancer drug Avastin (active ingredient Bevacizumab).

Since last year, Celltrion has been working on a global patent agreement with the original drug developer to enable early sales of the Avastin biosimilar 'CT-P16' immediately upon global approval. With this agreement, the product can be launched stably without patent disputes.

Celltrion plans to launch the product in major global markets starting September this year for key indications and therapies including metastatic colorectal cancer, non-small cell lung cancer, and ovarian cancer. However, in Korea, a patent validity trial between another company and the original drug developer is ongoing, and Celltrion is monitoring its impact accordingly.

CT-P16 is a biosimilar of Avastin used to treat non-small cell lung cancer, metastatic colorectal cancer, ovarian cancer, metastatic breast cancer, glioblastoma, and other conditions. Last year, Celltrion applied for marketing approval of CT-P16 to the Ministry of Food and Drug Safety, the US FDA, and the European EMA, and expects approval within this year.

Once CT-P16 is launched, Celltrion will secure its third anticancer antibody biosimilar following the already global market-introduced hematologic cancer treatment 'Truxima' and breast cancer treatment 'Herzuma,' thereby building a strong portfolio in the anticancer drug field.

A Celltrion official stated, "We have amicably completed the global patent agreement with the original drug developer and finalized the preliminary work for the stable market launch of CT-P16," adding, "We will do our best to complete the ongoing approval process and promptly introduce CT-P16 to the market."

This content was produced with the assistance of AI translation services.